
Biogen Pharmachem Industries Ltd Valuation Shifts Signal Elevated Price Risk
2026-11-05 08:00:30Biogen Pharmachem Industries Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has seen its valuation parameters deteriorate sharply, moving from a 'risky' to a 'very expensive' rating. With a price-to-earnings (P/E) ratio soaring to 45.39 and a price-to-book value (P/BV) of just 0.27, investors face a complex valuation landscape amid weak returns and negative capital employed metrics.
Read More
Biogen Pharmachem Industries Ltd Falls to 52-Week Low of Rs 0.24 as Sell-Off Deepens
2026-10-15 09:40:36For the second consecutive session, Biogen Pharmachem Industries Ltd has seen its share price decline further, hitting a fresh 52-week low of Rs 0.24 on 15 Oct 2026. This drop extends the stock’s year-long slide, which now stands at a steep 64.79% loss, significantly underperforming the Sensex’s 11.24% decline over the same period.
Read More
Biogen Pharmachem Industries Ltd is Rated Strong Sell
2026-10-08 10:10:27Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 September 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 08 October 2026, providing investors with the latest insights into its performance and outlook.
Read More
Markets Rally, But Biogen Pharmachem Industries Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off
2026-09-11 09:36:18Despite a broadly positive market environment, Biogen Pharmachem Industries Ltd has plunged to a fresh 52-week low of Rs 0.25 on 11 Sep 2026, marking a steep 64.94% decline over the past year and underperforming the Sensex by a wide margin.
Read MoreDisclosure Under Regulation 32(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015
03-Nov-2026 | Source : BSEPFA
Board Meeting Outcome for Outcome Of Board Meeting Held On 03Rd November 2026.
03-Nov-2026 | Source : BSEPursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company in their meeting held on today i.e. Tuesday 03rd November 2026. at the Registered Office of the Company and transacted the following major businesses:
Regulation 33 Read With Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations")
03-Nov-2026 | Source : BSEPFA
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
Biogen Pharmachem Industries Ltd has announced 1:6 bonus issue, ex-date: 15 May 26
No Rights history available